Find Dodecyl Maltoside manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 69227-93-6, N-dodecyl-beta-d-maltoside, Lauryl maltoside, Dodecyl maltoside, N-dodecyl b-d-maltoside, N-dodecyl beta-d-maltoside
Molecular Formula
C24H46O11
Molecular Weight
510.6  g/mol
InChI Key
NLEBIOOXCVAHBD-QKMCSOCLSA-N
FDA UNII
DI107E57B4

Dodecyl Maltoside
Dodecyl Maltoside is an alkyl disaccharide compound and polar surfactant, with potential adenoviral transduction-enhancing activity. Upon administration as a bladder wash, dodecyl maltoside (DDM) acts as a surfactant and enhances adenoviral transduction and infection of the bladder urothelium. This may allow for an efficient delivery of oncolytic viruses in the treatment of bladder cancer.
1 2D Structure

Dodecyl Maltoside

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-6-dodecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
2.1.2 InChI
InChI=1S/C24H46O11/c1-2-3-4-5-6-7-8-9-10-11-12-32-23-21(31)19(29)22(16(14-26)34-23)35-24-20(30)18(28)17(27)15(13-25)33-24/h15-31H,2-14H2,1H3/t15-,16-,17-,18+,19-,20-,21-,22-,23-,24-/m1/s1
2.1.3 InChI Key
NLEBIOOXCVAHBD-QKMCSOCLSA-N
2.1.4 Canonical SMILES
CCCCCCCCCCCCOC1C(C(C(C(O1)CO)OC2C(C(C(C(O2)CO)O)O)O)O)O
2.1.5 Isomeric SMILES
CCCCCCCCCCCCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O
2.2 Other Identifiers
2.2.1 UNII
DI107E57B4
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Dodecyl Maltoside

2. Dodecyl(-beta-d-)maltoside

3. Lauryl Maltoside

4. N-dodecyl-beta-d-maltoside

2.3.2 Depositor-Supplied Synonyms

1. 69227-93-6

2. N-dodecyl-beta-d-maltoside

3. Lauryl Maltoside

4. Dodecyl Maltoside

5. N-dodecyl B-d-maltoside

6. N-dodecyl Beta-d-maltoside

7. N-dodecyl-

8. A-d-maltoside

9. Dodecyl Beta-maltoside

10. Dodecyl Beta-d-maltoside

11. Chebi:43769

12. Dodecyl B-d-maltopyranoside

13. Di107e57b4

14. Mfcd00043012

15. (2r,3r,4s,5s,6r)-2-(((2r,3s,4r,5r,6r)-6-(dodecyloxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2h-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol

16. Dodecyl 4-o-alpha-d-glucopyranosyl-beta-d-glucopyranoside

17. N-dodecyl-b-d-maltoside

18. Unii-di107e57b4

19. Lauryl Beta-maltoside

20. Dodecyl -d-maltoside

21. Lauryl Beta-d-maltoside

22. N-dodecyl-i(2)-d-maltoside

23. Schembl411624

24. Chembl1234047

25. Dtxsid30988948

26. Lauryl-.beta.-d-maltoside

27. Zinc16051829

28. N-dodecyl .beta.-d-maltoside

29. Akos016011222

30. Dodecyl 4-o-hexopyranosylhexopyranoside

31. Ds-6568

32. (2r,3r,4s,5s,6r)-2-((2r,3s,4r,5r,6r)-6-(dodecyloxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2h-pyran-3-yloxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol

33. (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-6-dodecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

34. Hy-128974

35. N-dodecyl Beta-d-maltoside, >=98% (gc)

36. Cs-0102968

37. 1-o-n-dodecyl-.beta.-dmaltopyranoside

38. F14800

39. 227d936

40. A866883

41. N-dodecyl Beta-d-maltoside, Bioxtra, >=98% (gc)

42. B-d-glucopyranoside, Dodecyl 4-o-a-d-glucopyranosyl-

43. Q27120527

44. Beta-d-glucopyranoside, Dodecyl 4-o-alpha-d-glucopyranosyl-

45. Dodecyl Alpha-d-glucopyranosyl-9(1->4)-beta-d-glucopyranoside

46. Wurcs=2.0/2,2,1/[a2122h-1b_1-5_1*occcccccccccc][a2122h-1a_1-5]/1-2/a4-b1

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 510.6 g/mol
Molecular Formula C24H46O11
XLogP31.4
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count11
Rotatable Bond Count16
Exact Mass510.30401228 g/mol
Monoisotopic Mass510.30401228 g/mol
Topological Polar Surface Area179 Ų
Heavy Atom Count35
Formal Charge0
Complexity554
Isotope Atom Count0
Defined Atom Stereocenter Count10
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Detergents

Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)


USDMF

read-more
read-moreread-more

01

PREP
Not Confirmed

03

PREP
Not Confirmed

04

Sigma F And D Div Ltd

U.S.A

USDMF

arrow
PREP
Not Confirmed
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.


Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Microorganism

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 05, 2024

blank

01

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside

Therapeutic Area : Oncology

Highest Development Status : Undisclosed

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.

Product Name : Undisclosed

Product Type : Microorganism

Upfront Cash : Inapplicable

June 05, 2024

blank

Details:

Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.


Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Microorganism

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 01, 2023

blank

02

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.

Product Name : Undisclosed

Product Type : Microorganism

Upfront Cash : Inapplicable

November 01, 2023

blank

Details:

CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent which is being investigated in combination with keytruda® (pembrolizumab) in non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG).


Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Microorganism

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 01, 2023

blank

03

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab

Therapeutic Area : Oncology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent which is being investigated in combination with keytruda® (pembrolizumab) in non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin...

Product Name : Undisclosed

Product Type : Microorganism

Upfront Cash : Inapplicable

May 01, 2023

blank

Details:

CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial in combination with keytruda for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.


Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Microorganism

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 10, 2023

blank

04

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab

Therapeutic Area : Oncology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial in combination with keytruda for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.

Product Name : Undisclosed

Product Type : Microorganism

Upfront Cash : Inapplicable

April 10, 2023

blank

Details:

CG0070, is an intravesically delivered selective oncolytic immunotherapy agent that is currently in a Phase 3 trial for the treatment of BCG-unresponsive NMIBC.


Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Microorganism

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 24, 2022

blank

05

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

Details : CG0070, is an intravesically delivered selective oncolytic immunotherapy agent that is currently in a Phase 3 trial for the treatment of BCG-unresponsive NMIBC.

Product Name : Undisclosed

Product Type : Microorganism

Upfront Cash : Inapplicable

October 24, 2022

blank

Details:

The first poster presentation reports on efficacy and safety data from a global Phase 2 study of CG0070 in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer.


Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Microorganism

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 04, 2022

blank

06

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

Details : The first poster presentation reports on efficacy and safety data from a global Phase 2 study of CG0070 in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer.

Product Name : Undisclosed

Product Type : Microorganism

Upfront Cash : Inapplicable

June 04, 2022

blank

Details:

Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.


Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Microorganism

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 30, 2020

blank

07

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.

Product Name : Undisclosed

Product Type : Microorganism

Upfront Cash : Inapplicable

June 30, 2020

blank

Details:

CG0070 is a Microorganism drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.


Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Microorganism

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 13, 2020

blank

08

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

CG Oncology

U.S.A
arrow
PREP
Not Confirmed

Details : CG0070 is a Microorganism drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.

Product Name : Undisclosed

Product Type : Microorganism

Upfront Cash : Inapplicable

May 13, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for 69227-93-6 / Dodecyl Maltoside API manufacturers, exporters & distributors?

Dodecyl Maltoside manufacturers, exporters & distributors 1

44

PharmaCompass offers a list of Dodecyl Maltoside API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dodecyl Maltoside manufacturer or Dodecyl Maltoside supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dodecyl Maltoside manufacturer or Dodecyl Maltoside supplier.

PharmaCompass also assists you with knowing the Dodecyl Maltoside API Price utilized in the formulation of products. Dodecyl Maltoside API Price is not always fixed or binding as the Dodecyl Maltoside Price is obtained through a variety of data sources. The Dodecyl Maltoside Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Dodecyl Maltoside

Synonyms

69227-93-6, N-dodecyl-beta-d-maltoside, Lauryl maltoside, N-dodecyl b-d-maltoside, N-dodecyl beta-d-maltoside, N-dodecyl-

Cas Number

69227-93-6

Unique Ingredient Identifier (UNII)

DI107E57B4

About Dodecyl Maltoside

Dodecyl Maltoside is an alkyl disaccharide compound and polar surfactant, with potential adenoviral transduction-enhancing activity. Upon administration as a bladder wash, dodecyl maltoside (DDM) acts as a surfactant and enhances adenoviral transduction and infection of the bladder urothelium. This may allow for an efficient delivery of oncolytic viruses in the treatment of bladder cancer.

Dodecyl Maltoside Manufacturers

A Dodecyl Maltoside manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dodecyl Maltoside, including repackagers and relabelers. The FDA regulates Dodecyl Maltoside manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dodecyl Maltoside API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Dodecyl Maltoside Suppliers

A Dodecyl Maltoside supplier is an individual or a company that provides Dodecyl Maltoside active pharmaceutical ingredient (API) or Dodecyl Maltoside finished formulations upon request. The Dodecyl Maltoside suppliers may include Dodecyl Maltoside API manufacturers, exporters, distributors and traders.

click here to find a list of Dodecyl Maltoside suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Dodecyl Maltoside USDMF

A Dodecyl Maltoside DMF (Drug Master File) is a document detailing the whole manufacturing process of Dodecyl Maltoside active pharmaceutical ingredient (API) in detail. Different forms of Dodecyl Maltoside DMFs exist exist since differing nations have different regulations, such as Dodecyl Maltoside USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Dodecyl Maltoside DMF submitted to regulatory agencies in the US is known as a USDMF. Dodecyl Maltoside USDMF includes data on Dodecyl Maltoside's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dodecyl Maltoside USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Dodecyl Maltoside suppliers with USDMF on PharmaCompass.

Dodecyl Maltoside GMP

Dodecyl Maltoside Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Dodecyl Maltoside GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dodecyl Maltoside GMP manufacturer or Dodecyl Maltoside GMP API supplier for your needs.

Dodecyl Maltoside CoA

A Dodecyl Maltoside CoA (Certificate of Analysis) is a formal document that attests to Dodecyl Maltoside's compliance with Dodecyl Maltoside specifications and serves as a tool for batch-level quality control.

Dodecyl Maltoside CoA mostly includes findings from lab analyses of a specific batch. For each Dodecyl Maltoside CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Dodecyl Maltoside may be tested according to a variety of international standards, such as European Pharmacopoeia (Dodecyl Maltoside EP), Dodecyl Maltoside JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dodecyl Maltoside USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty